These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23462656)

  • 1. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer.
    Dingle IF; Mishoe AE; Nguyen SA; Overton LJ; Gillespie MB
    Otolaryngol Head Neck Surg; 2013 May; 148(5):746-52. PubMed ID: 23462656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers.
    Almeida JP; Vartanian JG; Kowalski LP
    Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):342-6. PubMed ID: 19380354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory.
    Chen AY; Frankowski R; Bishop-Leone J; Hebert T; Leyk S; Lewin J; Goepfert H
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):870-6. PubMed ID: 11448365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
    Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
    Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients.
    Choi EK; Oh JK; Chung YA; Jeong H; Choi H; Jo K
    Int J Med Sci; 2024; 21(3):492-495. PubMed ID: 38250604
    [No Abstract]   [Full Text] [Related]  

  • 6. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy.
    Lin BM; Starmer HM; Gourin CG
    Laryngoscope; 2012 Jul; 122(7):1518-25. PubMed ID: 22467530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in quality of life and related factors in thyroid cancer patients with radioactive iodine remnant ablation].
    Yoo SH; Choi-Kwon S
    J Korean Acad Nurs; 2013 Dec; 43(6):801-11. PubMed ID: 24487996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors of
    Hollingsworth B; Senter L; Zhang X; Brock GN; Jarjour W; Nagy R; Brock P; Coombes KR; Kloos RT; Ringel MD; Sipos J; Lattimer I; Carrau R; Jhiang SM
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4085-4093. PubMed ID: 27533304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysphagia after nonsurgical head and neck cancer treatment: patients' perspectives.
    Wilson JA; Carding PN; Patterson JM
    Otolaryngol Head Neck Surg; 2011 Nov; 145(5):767-71. PubMed ID: 21746839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
    Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
    J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
    J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.
    Almeida JP; Sanabria AE; Lima EN; Kowalski LP
    Head Neck; 2011 May; 33(5):686-90. PubMed ID: 21484917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of dysphagia on quality-of-life in nasopharyngeal carcinoma.
    Lovell SJ; Wong HB; Loh KS; Ngo RY; Wilson JA
    Head Neck; 2005 Oct; 27(10):864-72. PubMed ID: 16114007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dysphagia on quality of life after treatment of head-and-neck cancer.
    Nguyen NP; Frank C; Moltz CC; Vos P; Smith HJ; Karlsson U; Dutta S; Midyett A; Barloon J; Sallah S
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):772-8. PubMed ID: 15708256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication.
    Allweiss P; Braunstein GD; Katz A; Waxman A
    J Nucl Med; 1984 Jul; 25(7):755-8. PubMed ID: 6737074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life impact of external beam radiotherapy for advanced thyroid carcinoma.
    Gal TJ; Streeter M; Burris J; Kudrimoti M; Ain KB; Valentino J
    Thyroid; 2013 Jan; 23(1):64-9. PubMed ID: 22971127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xerostomia after treatment for oral and oropharyngeal cancer using the University of Washington saliva domain and a Xerostomia-Related Quality-of-Life Scale.
    Rogers SN; Johnson IA; Lowe D
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):16-23. PubMed ID: 19679404
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.